Claims
- 1. A method of treating cancer in a vertebrate comprising:
administering to the vertebrate an effective tumor-growth-inhibiting amount of a compound, its pharmaceutically acceptable salt or pro-drug ester, having the following structure: 7wherein:
R1, R2, R5, R7, and R8, are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups, R3, R4, and R6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C12 alkyl, unsaturated C1-C12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups, X1 and X2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond.
- 2. The method of claim 1, wherein the average daily amount administered is between about 0.1 mg per day per kilogram of the vertebrate to about 100 mg per day per kilogram of the vertebrate.
- 3. The method of claim 1, wherein the chiral center beta to R2 and beta to X1 is in the S-configuration.
- 4. The method of claim 1, wherein the dashed bond represents a carbon-carbon double bond.
- 5. The method of claim 1, wherein R3, and R4 are both hydrogen.
- 6. The method of claim 1, wherein the chemical backbone of the compound, salt or pro-drug ester substantially retains a substantially planar preferred structure.
- 7. The method of claim 1, wherein the vertebrate is a human.
- 8. The method of claim 6, wherein the vertebrate is a human.
- 9. The method of claim 7, wherein the compound is (−)-phenylahistin, its pharmaceutically acceptable salt or pro-drug ester.
- 10. The method of claim 8, wherein the compound is (−)-phenylahistin, its pharmaceutically acceptable salt or pro-drug ester.
- 11. A method of treating a cancer selected from at least one of the following, lung cancer, stomach cancer, colon cancer, ovarian cancer, cancer of the central nerve system, kidney cancer, and melanoma, in a vertebrate comprising:
administering to the vertebrate an effective tumor-growth-inhibiting amount of a compound, its pharmaceutically acceptable salt or pro-drug ester, having the following structure: 8wherein:
R1, R2, R5, R7, and R8 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C24 alkyl, unsaturated C1-C24 alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, substituted nitro, phenyl, and substituted phenyl groups, R3, R4, and R6 are each separately selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C1-C12 alkyl, unsaturated C1-C12 alkenyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, and substituted nitro groups,
X1 and X2 are separately selected from the group consisting of an oxygen atom, and a sulfur atom, and the dashed bond represents a bond selected from the group consisting of a carbon-carbon single bond and a carbon-carbon double bond.
- 12. The method of claim 11, wherein the average daily amount administered is between about 0.1 mg per day per kilogram of the vertebrate to about 100 mg per day per kilogram of the vertebrate.
- 13. The method of claim 11, wherein the chiral center beta to R2 and beta to X1 is in the S-configuration.
- 14. The method of claim 11, wherein the dashed bond represents a carbon-carbon double bond.
- 15. The method of claim 11, wherein R3, and R4 are both hydrogen.
- 16. The method of claim 11, wherein the chemical backbone of the compound, salt or pro-drug ester substantially retains a substantially planar preferred structure.
- 17. The method of claim 11, wherein the vertebrate is a human.
- 18. The method of claim 16, wherein the vertebrate is a human.
- 19. The method of claim 17, wherein the compound is (−)-phenylahistin, its pharmaceutically acceptable salt or pro-drug ester.
- 20. The method of claim 18, wherein the compound is (−)-phenylahistin, its pharmaceutically acceptable salt or pro-drug ester.
PRIORITY CLAIM
[0001] This application is a continuation of, and claims priority from, U.S. Provisional Application Ser. No. 09/440,316, filed Nov. 12, 1999, U.S. Pat. No. ______, which application claimed priority from U.S. Provisional Application Ser. No. 60/108,211, PHENYLAHISTIN AS AN ANTI-TUMOR COMPOUND, filed Nov. 12, 1998, by Fukumoto et al., and also claimed priority from U.S. Provisional Application Ser. No. 60/108,736, PHENYLAHISTIN AS AN ANTI-TUMOR COMPOUND, filed Nov. 17, 1998, by Fukumoto et al.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60108211 |
Nov 1998 |
US |
|
60108736 |
Nov 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09440316 |
Nov 1999 |
US |
Child |
09995851 |
Nov 2001 |
US |